*|MC:SUBJECT|*
bioRN News January 2025
Dear *|FNAME|* *|LNAME|*,

Welcome in 2025! 
We are delighted to be able to bring you a wealth of exciting and profitable information from our Life Science Cluster in the bioRN Newsletter in 2025. 
Today you are going to read more about the top of our list activities in January:

In January, the bioRN Lounge got off to a brilliant start with around 100!! participants (an absolute attendance record)! Professor Peter Loskill captivated the audience with his impuls >>𝐎𝐫𝐠𝐚𝐧-𝐨𝐧-𝐂𝐡𝐢𝐩: 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐡𝐮𝐦𝐚𝐧 𝐌𝐨𝐝𝐞𝐥 𝐒𝐲𝐬𝐭𝐞𝐦𝐬 𝐟𝐨𝐫 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞<<
and gave insights into the latest state of research on retina-on-chip, heart-muscle-on-chip and cancer-on-chip.

A new highligh event for the region -  German Biotechnology Days 2025, taking place in Heidelberg for the first time -  is already making us look forward to 9 and 10 April: 
  • bioRN will be representing the life science ecosystem to around 1000 expected guests from Germany and abroad at the specially organised bioRN Village. Numerous member companies and institutions will also be represented in the area. 
  • The wide-ranging conference program promises plenty of opportunity for lively discussions and, with the introduction of a partnering option, the opportunity for planned meetings! 
  • Would you like to register? No problem: as a bioRN member you will receive a discounted ticket. All information about the program and registration can be found on the website. 
See you there? 

Further bioRN highlights in brief: 
  • the bioRN M2M Member to Member interview with Nanobot is available on our website: Learn more about the magic and the benefit of professionalised scientific storytelling: Here is the Video (scroll to section >past M2M Videos<)
  • bioRN Think Tank Investment: Kick-off meeting 2025 defined roadmap:  Further development of concepts to close financing gaps for startups, organisation of the second Private Investors Day and further expansion of the successful ‘Life Science Investors Day Heidelberg’ format. The members of the working group are starting their project work with great commitment. 
  • EIT Health Catapult Semifinals: 29 Semifinalists present their innovations at the on-demand platform and you can watch the videos until 15 February! 
    • bioRN is leading the Catapult program since 2024 and together with 2 partners enables the startups to write their success stories with the profound support of numerous mentors. 
    • Get access here
  • NEW: bioRN MarCom Breakfast on February 27 on the topic: Unlocking AI for your marketing team! 
    • Feeling overwhelmed by AI? You’re not alone! If you’re leading a MarCom team or working in a MarCom team and trying to wear many hats, whilst navigating the mass of AI tools, this event is for you. Find more details and registration here:
Don´t miss further news from the network at the bioRN website and get the latest news about funding and growth opportunities at 05 | Opportunities.

Kind regards,

Stephanie Füller 
PR Manager
bioRN Life Science Cluster 
LinkedIn
Twitter
Website
01 | Research Highlights & News
02 | New Members
03 | Event Spotlights
04 | Event Calendar & Discounts
05 | Opportunities
06 | Open Positions
01 | Research Highlights & News

New Publication from AbbVie and Sciomics: Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays [more]

Bayer AG: BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial [more]

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy [more]

curATime is looking for partners! [more]

DKFZ:
  • New approach to fighting cancer: energy trap for tumor cells [more]
  • Epigenetics ensures placenta functioning [more]
  • New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells [more]
EMBL: 
  • BioChatter: making large language models accessible for biomedical research [more]
  • Epigenetics ensures placenta functioning [more]
  • New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells [more]
  • From snapshots to motion: watching biology in action [more]
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma [more]

Heidelberg University: New weapons against viruses [more]

Heidelberg University Hospital (UKHD): How the Ebola virus multiplies in cells [more]

HI-STEM: 
  • New Publication: Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling [more]
  • New Publication: Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype [more]

With lipid nanoparticles (LNPs), PROGEN offers an alternative drug delivery tool for the gene therapy market [more]

YUMAB and InSCREENeX are developing an innovative “Mammalian Display” screening platform to accelerate antibody development. [more]

02 | New Members
Alcedis is a globally operating, leading full-service CRO with over 30 years of experience in clinical research. As a member of the Huma Group, they combine deep expertise with innovative AI-driven technologies to conduct clinical trials efficiently and accurately – from Phase I to market authorization, medical device projects, and real-world evidence. Their in-house competence centers for clinical operations, data management, and regulatory affairs drive advancements in drug and medical device development as well as patient care.
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.
Akribion is exploring applications in oncology, autoimmune diseases, fibrosis, and infectious diseases, as the technology can be quickly adapted to target different biomarkers and cells.
At GeneTechX, they are developing a nutrigenomics platform that combines genetics and nutritional science to create personalized dietary solutions. Leveraging advanced gene-editing technologies like PrimeCRISPR, they investigate the intricate relationships between genes, diet, and health outcomes.
By identifying genetic variations that affect nutrient metabolism, GeneTechX delivers tailored nutrition strategies to enhance health and prevent disease, setting a new standard in precision nutrition.
Menarini Biotech (MBH) is a leading CDMO specializing in Process Development and GMP manufacturing across various therapeutic areas. With a mission to be a reliable, agile, and innovative partner, MBH empowers its customers to bring life-saving biotherapeutics to patients through expertise in drug development.
From lab to production, cutting-edge technology accelerates processes, optimizes yields, and ensures precision at every stage. Guided by a vision of pioneering scientific breakthroughs, MBH applies innovative technologies to help find cures for difficult-to-treat diseases—transforming research insights into seamless clinical development.

03 | Event Spotlights

04 | Event Calendar & Discounts
Expand your Discovery Power with BD Biosciences
February 11, 2025 - Heidelberg, Germany >>

 
BiotechGate Digital Partnering
February 17–21, 2025 - Digital Partnering >>
BioRN members can benefit with a Free Premium Access.
bioRN M2M Member to Member featuring HS Analysis
February 19, 2025 - Online >>

 
Webinar: Automating antibiotic discovery in academia: A collaborative screening effort to identify novel TB therapeutics
February 19, 2025 - Online >>

 
bioRN Lounge featuring Peter Mark–  Thermo Fisher Scientific
25 February 2025 - Heidelberg >>

 
bioRN MarCom Breakfast
27 February 2025 - Heidelberg >>

 
Transforming Science Day 2025
February 25, 2025 - Heidelberg, EMBL >>

 
Bio-Europe Spring
March 17–19, 2025 - Milan, Italy
March 25–26, 2025 - Digital Partnering >>
10% discount off registration for BioRN Members.
Advanced Therapies 2025
March 18–19, 2025 - London, UK  >>
20 % discount for BioRN Members.
German Biotechnology Days 2025
April 09-10, 2025 - Heidelberg, Germany >>
BioRN is the regional host!
BioVaria 2025
April 28-29, 2025 - Munich, Germany >>
LSX World Congress
April 28-30, 2025 - London, UK >>
20% discount for BioRN Members.
CONTACT 2025 – Life Science Job Fair
May 21, 2025 - Heidelberg, DKFZ >>
BIO International Convention
June 16-19, 2025 - Boston, USA  >>

05 | Opportunities


In this section we provide selected information on funding calls and events. All information is also provided on our website

Pitches & Prices:
  • Innovation Award 2025, German Bioregions: Application Deadline at 14 February 2025.  [more] 
  • Road to START Summit 2025 [more]
  • IDEE-Förderpreis für innovative Unternehmensgründungen von Frauen. Application Deadline at 31 July 2025.   [more]
  • Safe the date: Life Science Investors´Day Heidelberg, 25 September  [more]
Knowledge Transfer:
  • ZIM International: 35. Ausschreibung im Netzwerk IraSME: Brasilien, Flandern (Belgien), Luxewmburg, Österreich, Tschechische Republik, Türkei, Wallonien (Belgien)  [more] 
Internationalisation:
  • Markterschließungsprojekt: Gesundheitswirtschaft/Medizintechnik-Angola [more]
  • Geschäftsanbahnung für Deutsche Unternehmen aus dem Bereich Gesundheitswirtschaft mit Fokus auf Pharmaindustrie und Biotechnologie [more]
Open Calls:
  • Go-bio next: Application Deadline 15 March 2025 - Die Neuauflage der Förderrichtlinie, genannt „GO-Bio next“, hat weiterhin die für biotechnologische Forschungsprojekte typischen langen Entwicklungszeiträume und den hohen Finanzbedarf im Blick. [more]
  • Pharmacogenomic strategies for personalised medicine apporaches (PGxPM2025): Application Deadline 18 February 2025   [more] 
  • Förderaufruf: Innovative Bioproduktion für eine klimaneutrale Industrie: Application Deadline 3 March 2025
  • Förderung interaktiver Technologien für die kardio-onkologische Nachsorge. [more]
  • Förderung von länderübergreifenden wissenschaftsinitiierten pragmatischen vergleichenden Wirksamkeitsstudien bei nicht übertragbaren Krankheiten im Rahmen der Europäischen Partnerschaft ERA4Health (EffecTrial) [more]
  • Förderung von Projekten zum Thema „Ethische, rechtliche und soziale Aspekte von Zukunftsthemen in den modernen Lebenswissenschaften sowie entwicklungsbiologische Forschung und ihre mögliche Anwendung am Menschen“ 
    [more]
  • Förderung von Projekten zum Thema  "Klinische Validierung innovativer medizintechnischer Lösungen" [more]
  • Förderung von interdisziplinären Pilotprojekten zum Thema "neurobiologisch inspirierte künstliche Intelligenz"  [more]
  • Förderung von von Projekten zum Thema "KMU innovativ" Biomedizin [more]
Other:
Cybersicherheits-Check für kleine und mittlere Unternehmen
[more]
The free certification in the context of iRISE EU is possible until end of 2025
[more] 

06 | Open Positions

BioMed X Institute:

  • New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics: Group Leader [more]
  • New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics: Postdoctoral Researchers [more]
  • New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics: Research Assistants [more]

iQMedix:

  • Molekularbiologin/en – Onkologie  (m/w/d) [more]

ProtaGene:

  • Technician / Technischer Assistent (m/w/d) in Heidelberg [more]

SPT Labtech:

  • Field Service Engineer (m/w/d) [more]
  • Territory Sales Manager (m/w/d) [more]
Tweet Tweet
Forward Forward
Share Share

Imprint


Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Responsible for the content:
Dr. Julia Schaft

Editor: Stephanie Füller

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|*

Commercial Register: Mannheim, HRB 704801
VAT ID: DE 2630 64 014

unsubscribe from this list    update subscription preferences 

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*